| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Thomas Edward Hamilton is Director at LRMR, with reported holdings spanning 2 companies. Thomas Edward Hamilton's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $1.8M at current prices.
Our model assigns Thomas Edward Hamilton a middling insider score of 51/100, based on 6 past trades. Over a 12-month horizon, 50.0% of those trades were profitable, with an average 12-month return of -25.6%.
Thomas Edward Hamilton's largest disclosed position is in LRMR as Director, worth about $1.8M. Net of sales, the LRMR filings show accumulation of 581,378 shares.
Thomas Edward Hamilton has 23 Form 4 filings on record from May 2019 to July 2026, across 2 companies: Director at Larimar Therapeutics (LRMR), 2020–2026; Director at Annaly Capital Management (NLY), 2019–2026.
The 27 reported transactions were 15 option or other derivative awards, 9 open-market purchases, 2 other transactions and 1 open-market sale.
Counted by filing, the open-market trades come to 7 purchases worth about $4.7M and 1 sale worth about $734K.
The largest open-market purchase was 200,000 shares of NLY at an average $5.96 on May 15, 2020, about $1.2M.
The only open-market sale was 80,000 shares of NLY at an average $9.18 on May 3, 2021, about $734K. Twelve months later NLY was down 19%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jul 6, 2026 | LRMR Larimar Therapeutics, Inc. | Director | Buy | 50,000 | $3.34 | $166,890.00 | +7.5% | -13.1% | - | |
| Feb 27, 2026 | LRMR Larimar Therapeutics, Inc. | Director | Buy | 100,000 | $5.00 | $500,000.00 | +17.7% | -34.4% | - | |
| Feb 16, 2024 | LRMR Larimar Therapeutics, Inc. | Director | Buy | 57,208 | $8.74 | $499,997.92 | +11.3% | -41.9% | -73.9% | |
| Sep 16, 2022 | LRMR Larimar Therapeutics, Inc. | Director | Buy | 317,460 | $3.15 | $999,999.00 | +167.0% | +42.5% | +32.5% | |
| Jun 30, 2021 | LRMR Larimar Therapeutics, Inc. | Director | Buy | 56,710 | $8.75 | $496,212.50 | +42.5% | +24.7% | -80.0% | |
| May 3, 2021 | NLY Annaly Capital Management Inc | Director | Sell | 80,000 | $9.18 | $734,432.00 | -100% | -5.3% | -18.9% | |
| May 15, 2020 | NLY Annaly Capital Management Inc | Director | Buy | 200,000 | $5.96 | $1,192,920.00 | +153.8% | - | - | |
| May 17, 2019 | NLY Annaly Capital Management Inc | Director | Buy | 90,000 | $9.47 | $852,294.00 | -900.0% | - | - |